<<< Go to start <<<
| Page 4 of 4 | 1 | 2 | 3 | 4 |
It’s a less-than-$20 stock today that could
easily be $100 in the next few monthsYou may think I’m exaggerating when I tell you these kinds of returns are possible. But in the business of medicine, it’s news and test results that drive stock prices.
A Phase III study, with upcoming FDA approval – which this company is in the middle of pursuing right now – is the best news a medical company can have.
Successful Phase III tests mean a drug or medical treatment works. It means the company is about to start reaping the rewards of its investment.
It happens over and over again in the world of new drugs: 1) A small medical company introduces a valuable new medicine or treatment. 2) The FDA approves it. 3) Early investors get rich. For example…
When a pharmaceutical company called Amgen developed two new drugs in the early 1990s (Epogen to treat anemia and Neupogen to prevent infections in cancer patients), early investors made profits of 6,085%.
After Biogen launched its drug Avonex to treat multiple sclerosis in 1996, its stock shot up 667%.
When Idec Pharmaceuticals, a San Diego biotech company, introduced its cancer-tumor shrinking drug Rituxan, its stock went from $2 to $125. That’s an increase of 6,150%!
And keep in mind: An AIDS vaccine is for healthy people. In other words, it has about 1,000-times the patient potential of the other successful drugs I just mentioned.
I recommend you buy shares of this company right away. It’s still unbelievably cheap.
Keep in mind, you need only a very small stake in this company to have the potential for a huge payoff. In fact, I recommend you never put more than 4% of your portfolio into any one investment.
Believe me, if this company takes off as I expect, even with a small investment, our profits will be tremendous.
He continued his sales pitch with something else for which he is known: details of a £1,000 “report”. This, he said, included studies which “prove this vaccine works” and said it “provides further proof – in a very different kind of way – that this vaccine works”. All you had to do was buy his product.
If you are interested in investing in this company, I will send you a full Investigative Report, called The AIDS Vaccine – The Holy Grail of Medicine, which details 1) the studies that prove this vaccine works 2) the people behind this company, and 3) the reasons why this is such a smart investment.
This report will also detail an ‘unpublished’ study of this vaccine, presented at a National Institutes of Health (NIH) conference.
Technically, these results are public information. They were presented at a scientific conference sponsored by the NIH in 1997. But no one who attended the NIH conference ever spoke to Wall Street. And to the best of our knowledge, the information we’ll share with you is completely unknown outside of a very small group of AIDS researchers.
The reason this study is so important is because it provides further proof – in a very different kind of way – that this vaccine works. I believe that if the investment public and other Wall Street analysts knew about this study, this company’s share price would be a lot higher than it is right now.
I charge $1,000 to give investors a single investment selection such as this. Many people have been happy to pay that rate. And I think it’s a reasonable fee, considering 1) the level of research that goes into it and 2) the profit potential.
For people who want to receive my top technology selections throughout the year, I charge a discounted rate of $5,000 for 12 recommendations.
Porter Stansberry’s pitch continued:
Through a limited offer, because I want to introduce more people to my investment service, I am willing to send you all of the research details on this AIDS vaccine for only $149. You can do the math. That’s a huge savings.
And it gets even better. If you order now, I’ll cut the price in half. That means you will have the exact same valuable research in your hands for only $74.50, a tiny fraction of what others have paid. Think about what that means.
For about the cost of a decent dinner for two, you have the opportunity to completely change the outlook of your financial future. You could make back the money you’ve lost in the market. You could turn a small investment into a giant fortune.
As I mentioned earlier, all in all, we’ve spent more than $250,000 on the research that went into creating this report. Nobody else does this kind of research that I’m aware of – on Wall Street or off.
And there’s more giveaway goodies from Porter Stansberry. Today’s followers will recognise the patter:
When you order The AIDS Vaccine – The Holy Grail of Medicine, I’ll also send you 2 more of my recent Research Prospectus Reports, absolutely FREE.
You see, right now, there are two other medical breakthroughs I’m very excited about, which are also nearing the final stages of full U.S. government approval. Today, these stocks are extremely cheap. In a few months, I believe they both have the potential to increase at least 10 times in value.
FREE Research Prospectus Report #1: Heat Shock Proteins – The Biggest Cancer Development of the Decade
The narrative continued in similar vein to the VaxGen promotion. “How much money would a safe, pain-free treatment for cancer be worth..? A new treatment developed by a small company in New York… No more chemo.. No more radiation… No more surgery… Government-approved Phase III tests… Dave Lashmet and I… the single most promising medical technology I’ve ever seen…. It’s pain-free and side-effect free… can be used to fight any type of cancer.”
You’ll get a copy of this Research Report FREE – others have paid $416 for this information – when you order The AIDS Vaccine: The Holy Grail of Medicine.
While stocks last.